ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Early Everolimus Conversion For Renal Protection In Liver Transplantation: The Sooner The Better?

M. Tomeczkowicz, N. Sulejmani, A. Jantz, B. Summers, T. Larson, R. Salgia

Henry Ford Health System, Detroit, MI

Meeting: 2019 American Transplant Congress

Abstract number: D138

Keywords: Liver transplantation, Nephrotoxicity, Renal function, Tumor recurrence

Session Information

Session Name: Poster Session D: Liver: Immunosuppression and Rejection

Session Type: Poster Session

Date: Tuesday, June 4, 2019

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

*Purpose: Calcineurin inhibitors (CNI) are the mainstay of immunosuppressive therapy in transplantation; however, a major side effect limiting CNI use is nephrotoxicity. Mammalian target of rapamycin inhibitors (mTORi) are less likely to cause renal dysfunction and have demonstrated benefit in preserving renal function post-liver transplant (LT); however, few studies address the appropriate timing of mTORi conversion.

*Methods: This is an observational retrospective cohort study comparing renal function at 3 months post conversion to everolimus (EVR) along with a CNI based immunosuppressive regimen. Early initiation (EI) (conversion between 30 and 90 days post LT) was compared to delayed initiation (DI) (conversion greater than 90 days post LT) between June 2013 and May 2018. The primary outcome assessed the difference in estimated glomerular filtration rate (eGFR) utilizing the Modification of Diet in Renal Disease (MDRD) equation after 3 months of EVR therapy. Secondary outcomes assessed included incidence of biopsy proven acute rejection (BPAR), mortality, graft survival (GS), discontinuation of EVR and malignancy recurrence.

*Results: A total of 78 patients (pts) were included with 54 pts in the EI group and 24 pts in the DI group. Median (IQR) number of days to EVR conversion was 68 (45 to 89) days in the EI group and 142.5 (126 to 202) days in the DI group. Most pts were not converted to EVR sooner due to slow healing of post-operative wounds. The median (IQR) eGFR at the time of EVR conversion in the EI and DI groups was 76.5 (69 to 92) and 77 (63 to 93) mL/min per 1.73 m2, respectively, (p=0.913). The median (IQR) change in eGFR after 3 months post EVR initiation was 0 (-11 to 9) mL/min per 1.73 m2 in the EI group and 0 (-15.5 to 17) mL/min per 1.73 m2 in the DI group, (p=0.628). There was no difference in BPAR, mortality, GS or malignancy recurrence between the groups. EVR was most commonly discontinued due to mouth sores (5 pts in EI group), fatigue (3 pts in EI group and 2 pts in DI group), and diarrhea (4 pts in EI group).

*Conclusions: Switching patients to an EVR based immunosuppressive regimen early did not demonstrate a renal protective benefit at 3 months post conversion. Secondary outcomes did not differ between the two groups. Early conversion to EVR does not exude a renal protective benefit early post LT and could be delayed.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Tomeczkowicz M, Sulejmani N, Jantz A, Summers B, Larson T, Salgia R. Early Everolimus Conversion For Renal Protection In Liver Transplantation: The Sooner The Better? [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/early-everolimus-conversion-for-renal-protection-in-liver-transplantation-the-sooner-the-better/. Accessed May 9, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences